Slide1 l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 25

Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers PowerPoint PPT Presentation


  • 183 Views
  • Uploaded on
  • Presentation posted in: General

Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers. Core presentation prepared by Sophie Logez The Global Fund to fight AIDS, TB and Malaria Presented by Milan Smid, PQP .

Download Presentation

Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Slide1 l.jpg

Quality Assurancefor pharmaceutical products in international procurementApproach of major donors and procurers

Core presentation prepared by Sophie Logez

The Global Fund to fight AIDS, TB and Malaria

Presented by Milan Smid, PQP


Trends applied by major international donors and procurers l.jpg

Trends applied by major international donors and procurers

  • Focus on quality

  • Harmonization of quality policies and standards

  • Quality is prerequisite for successful tenders

  • The Global Fund to fight AIDS, TB and Malaria sets up an example

  • Similar criteria applied by others, e.g. UNITAID, GDF and UNFPA

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


T he global fund l.jpg

The Global Fund

“Making a “sustainable and significant” contribution

to the achievement of the Millennium Development Goals”

Guiding principles

  • Operate as a financial instrument

  • Make available and leverage additional financial resources

  • Support programs that evolve from national plans and priorities

  • Performance-based funding mechanism

Since 2002: 579 active grants in 144 countries (June 2010)

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Disease components distribution rounds 1 8 july 2009 l.jpg

Disease Components DistributionRounds 1-8, (July 2009)

Global Fund Resources by Disease Component

100% = US$ 15.9 billion

Percentages of total funds approved by the Board

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010

OP/140709/3


Rapid scaling up of results l.jpg

Rapid scaling up of results

Global Fund Top 3 result indicators (2010)

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


T he global fund psm policy and principles l.jpg

The Global Fund PSM Policy and Principles

  • Quality-assured products

    • Quality Assurance Policy for Pharmaceutical Products

  • Lowest possible price

  • Transparent, fair and competitive procurement

    • “Operational principles for Good Pharmaceutical Procurement”

  • National laws and international agreements

  • Build on existing systems

Recipients of grants are responsible for health products management

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Development of the global fund qa policy for pharmaceutical products l.jpg

Development of the Global Fund QA Policy for Pharmaceutical Products

2007

For limited and single source*:

- WHO PQ

- SRA approved

Or

GMP site

Or

GMP site and submission to PQ

* New definition of Single and limited source

2008/2009

For all ARVs, anti-TB, anti malarials:

- WHO PQ or

SRA approved

Or

- ERP recommended

2010

Interim exception

for some live saving anti malarial and

anti TB

2005

For limited and

single source:

- WHO PQ

- SRA approved

Or

- GMP site

Or

- GMP site and submission to WHO PQ

2002

For limited and single source:

- WHO PQ

- SRA approved

Or

- GMP manufacturing site

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Qa policy for pharmaceutical products as of 2009 l.jpg

QA Policy for Pharmaceutical Products (as of 2009)

  • Quality Criteria

  • For all products

  • Authorization for use in the recipient countries

  • For ARVs, anti-TB and anti-malarial products

    • WHO PQed or authorized by a SRA;

    • or

    • Recommended for use by an Expert Review Panel,

    • OnlyIf <2 WHO PQed or SRA authorized products available

  • Monitoring Quality

  • Monitoring quality of products all along the supply chain

  • Systematic random quality control testing

  • Recipients report testing results to Global Fund

  • Clinical Criteria

  • Medicines listed in WHO or national or institutional Standard Treatment Guidelines

+

+

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


The expert review panel l.jpg

The Expert Review Panel

  • A technical panel hosted by PQP

  • Coordinated by Head of PQ Assessment

  • Purposes:

    • To review the potential risks/benefits associated with the use of FPPs that are not yet WHO-prequalified or SRA-authorized.

    • To advise the Global Fund and GDF in its decision making

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


How erp works l.jpg

How ERP works

  • Review of product documentation:

    • at the request of the Global Fund/GDF, or

    • in response to GF/GDF invitation for EoI to submit dossiers.

  • A product is eligible for review by the ERP if:

    • Application to WHO Prequalification or application for marketing authorization to an SRA is accepted for assessment, and

    • Manufacturing site is GMP compliant (WHO/SRA/PICs)

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


How erp works11 l.jpg

How ERP works

  • ERP provides advice only, decision is made by the procurer

  • Time limited use (12 months)

    • Possibility of extending under certain circumstances

  • Not an alternative to PQ, but provides limited assurance of quality when there is no other option

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Categorization of products reviewed by erp l.jpg

Categorization of products reviewed by ERP

  • Products in Categories 1 and 2 can be considered, in principle, for time-limited procurement.

  • Products in Category 3 can be considered only if there is no other option and the risk of not treating the disease is considered to be higher than the risk of using the product

  • Products in Category 4 should not be considered for procurement under any circumstances.

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Products reviewed by the expert review panel since 2009 l.jpg

Products reviewed by the Expert Review Panel since 2009

  • Hosted by WHO at the request of the Board

  • Review the potential risks/benefits associated with the use of FPPs that are not yet WHO-prequalified or SRA-authorized and make recommendations to the Global Fund

  • 3 ERP set of reviews of dossiers based on an invitation for expression of interest to submit product dossiers

  • 98 product dossiers reviewed by ERP

  • 38 products permitted for use for a one year period

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Monitoring quality and pricing l.jpg

Monitoring Quality and Pricing

The Price and Quality Reporting system for key health products:

Element of the Market Dynamics Strategy

  • Make publicly available price and quality information

    • Transparency and accountability

    • Informed procurement decisions

    • demand forecasts

  • Monitor price and quality information

    • market conditions

    • Supplier performance

    • QA Policy compliance

  • Analyze procurement information for policy and decision-making purposes

“Essential foundation of sound market dynamics and procurement practices”

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Slide15 l.jpg

Monitoring Quality and Pricing

Recipients of grants are required to report procurement data of key health products:

  • - Antiretrovirals

  • - Antimalarial medicines

  • Antituberculosis medicines

  • - Bednets

  • - Condoms

  • - Rapid diagnostics tests

Health Products reported

http://www.theglobalfund.org/en/procurement/

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Accomplishments as of july 2010 l.jpg

Accomplishments as of July 2010

  • - over 700 million* US reported

  • - 712 registered users in 128 countries

  • 6,111 invoices

  • over 11,000 product purchases

Since

February 2009

Reporting into PQR since Feb 2009

*As of July 2010

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Distribution of products by quality criteria l.jpg

Distribution of Products by Quality Criteria

WHO prequalified and SRA approved products are purchased in priority, if available.

Currently, 95% (in units) of ARVs purchased by PRs are WHO PQed

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Publication of qc results l.jpg

Publication of QC Results

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Partnerships l.jpg

Partnerships

  • Close collaboration with WHO Prequalification Programme

    • Expert advice

    • QA Policy implementation: ERP management

  • WHO disease programs: HIV, Malaria, TB

  • Collaboration/information sharing with other donors and suppliers, such as UNITAID, PMI, UNICEF, UNDP

  • Working toward QA policy harmonization (eg. Global Drug Facility)

  • Regular communication with manufacturers

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Challenges l.jpg

Challenges

  • Increasing demands for

    • Malarial ,TB, and OI medicines of assured quality

    • Quality Control Laboratories compliant with Global Fund requirements

  • Strengthening National Regulatory Authority capacity and regulatory networking and harmonization

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Slide21 l.jpg

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Unitaid l.jpg

UNITAID

Strategically deployed funds in time-limited interventions

Innovative health financing mechanism raises money through air ticket levy from high and low income countries

Targeted interventions in global markets to improve patient access to health products

Works with and funds Partners to implement projects

Leverage investments to produce global public goods that generate positive externalities

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Slide23 l.jpg

93 countries already receive UNITAID support…

HIV / AIDS

49 recipient countries

Malaria

29 recipient countries

Tuberculosis

72 recipient countries

  • ACT

  • LLIN

  • AMFm

  • US$318 m

  • - First line TB

  • - Paediatric TB

  • MDR-TB

  • Diagnostics

  • US$211 m

  • - Paediatric ARV

  • - Second line ARV

  • PMTCT

  • US$476 m

- Cross cutting programs: US$109 m for PQ of drugs & diagnostics and transversal programs

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Quality assurance standard under construction l.jpg

Quality Assurance Standard(under construction)

Medicines are prequalified by WHO Pre qualification Programme or a Stringent Regulatory Authority (SRA)

For single or no prequalified source: GMP compliant and complete dossier submitted to WHO PQP or a SRA = technical evaluation of the product

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


Slide25 l.jpg

With thanks to Sophie Logez and Lorenzo Witherspoon for agreeing to use their presentations

Thank you for the attention

E-mail for correspondence: [email protected]

WHO Workshop on Prequalification of Medicines Programme,

Abu Dhabi, 11-13 October, 2010


  • Login